The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Health state utilities for metastatic breast cancer
Open accessAbstract
The aim of the study was to obtain United Kingdom-based societal preferences for distinct stages of metastatic breast cancer (MBC) and six common toxicities. Health states were developed based on literature review, iterative cycles of interviews and a focus group with clinical experts. They described the burden of progressive, responding and stable disease on treatment; and also febrile neutropenia, stomatitis; diarrhoea/vomiting; fatigue; hand-foot syndrome (grade 3/4 toxicities) and hair loss. One hundred members of the general public rated them using standard gamble to determine health state utility. Data were analysed with a mixed model analysis. The study sample was a good match to the general public of England and Wales by demographics and current quality of life. Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia). This study underlines the value that society place on the avoidance of disease progression and severe side effects in MBC. This may be the largest preference study in breast cancer designed to survey a representative general public sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Quality of life and pharmacoeconomics in clinical trials
Pater, J. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)82191-5 · Cited by 2,395
Measurement of health state utilities for economic appraisal
Torrance, G. W. (1986) · Journal of Health Economics · doi:10.1016/0167-6296(86)90020-2 · Cited by 2,203
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752 · cited 2×
“The review also highlighted how frequently disease-specific measures, such as the FACT-B (Brady et al, 1997) and European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire-BR23 (Sprangers et al, 1996), had been used.”
BackgroundMethodSprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Systematic Overview of Cost-Utility Assessments in Oncology
Earle, C. C., Chapman, R. H., Baker, C. S., Bell, C. M., Stone, P. W., Sandberg, E. A., & Neumann, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.18.3302 · Cited by 296
Cited by
The burden of OA-health services and economics
Leifer, V. P., Katz, J. N., & Losina, E. (2022) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.05.007 · Cited by 727
Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2276 · Cited by 31
Pelzer, U., Blanc, J.-F., Melisi, D., Cubillo, A., Von Hoff, D. D., Wang-Gillam, A., Chen, L.-T., Siveke, J. T., Wan, Y., Solem, C. T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.67 · Cited by 26
Factors Affecting Health-Related Quality of Life in Patients With Metastatic Breast Cancer
Park, M., Yu, S.-Y., Jeon, H.-L., & Song, I. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e29 · Cited by 13
Metadata
- Authors
- Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J.
- Venue
- British Journal of Cancer
- Published
- 2006-09
- Volume
- 95
- Issue
- 6
- Pages
- 683-690
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2020677481
- Cited by
- 354
- References
- 15
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health state utilities for metastatic breast cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6603326
- The paper
- Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603326
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.